Phase II Study of Calcitonin for Tumoral Calcinosis
Overview
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
Study Type
- Study Type: Interventional
- Study Design
- Primary Purpose: Treatment
Detailed Description
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin every 3 weeks. Ondansetron premedication and intravenous hydration are also administered. Patients are followed for disease progression and tumor recurrence.
Interventions
- Drug: calcitonin
Participating in This Clinical Trial
PROTOCOL ENTRY CRITERIA: –Disease Characteristics– Histologically confirmed tumoral calcinosis –Prior/Concurrent Therapy– Prior surgical resection of calcinotic lesion required
Gender Eligibility: All
Minimum Age: 0 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Collaborator
- Ann & Robert H Lurie Children’s Hospital of Chicago
- Overall Official(s)
- Craig B. Langman, Study Chair, Ann & Robert H Lurie Children’s Hospital of Chicago
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.